Bristol-Myers Squibb to buy Celgene in a cash and stock deal worth $74 billion

NEW YORK (AP) — Bristol-Myers Squibb to buy Celgene in a cash and stock deal worth $74 billion.

Copyright © 2019 The Associated Press. All rights reserved. This website is not intended for users located within the European Economic Area.